Actinium Pharmaceuticals is to initiate a Phase ll trial of Actimab-MDS for the treatment of myelodysplastic syndrome (MDS) next year.

The proposed trial is also aimed at studying Actimab-MDS as a conditioning regimen for patients with MDS and p53 genetic mutations who will undergo a bone marrow transplant.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

During the trial, patients will receive 4.0µCi/kg administered through a single infusion 12 days prior to receiving their bone marrow transplant.

Actimab-MDS is a part of Actinium’s new clinical initiative under the company’s CD33-Alpha programme, which combines the CD33 targeting ability of lintuzumab antibody with the cell-killing power of the alpha-particle-emitting radioisotope Actinium-225.

It is based on Actinium’s clinical development experience conducted on more than 100 patients and various clinical trials with Actimab-A in patients with acute myeloid leukemia (AML) and Actimab-M in patients with multiple myeloma (MM).

“There exists a compelling revenue opportunity for Actinium in the 2020-21 timeframe by launching possibly two therapies that have the potential for increasing curative outcomes from bone marrow transplants.”

Weill Cornell New-York Presbyterian Hospital Medicine professor and leukemia programme director Dr Gail Roboz will be the principal investigator for the trial, which will see the participation of MDS Clinical Research Consortium.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Actinium chairman and CEO Sandesh Seth said: “Actimab-MDS aligns perfectly with Actinium’s strengths as we have significant expertise and know in the area of bone marrow transplant as a result of our experience with our pivotal Phase lll programme, Iomab-B.

“Looking forward, we believe there exists for Actinium a compelling revenue opportunity in the 2020-2021 timeframe by launching not one but possibly two therapies that can provide safer myeloablation with the potential for increasing curative outcomes from bone marrow transplant.”

MDS is currently estimated to be prevalent in 60,000 patients in the US and 40,000 patients in the EU.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now